RecruitMe Clinical Trial

A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH-RISK CUTANEOUS SQUAMOUS CELL CARCINOMA
Study of Cemiplimab in Cutaneous Squamous Cell Carcinoma
Sponsor:Regeneron Pharmaceuticals, Inc.
Enrolling:Male and Female Patients
Minimum Age:18 years old
IRB Number:AAAS4125
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information:

The purpose of this study is determine if cemiplimab will prevent Cutaneous Squamous Cell Cancer (CSCC) from returning after surgery and radiation.

Do You Qualify?
Are you 18 years of age or older?YesNo
Were you diagnosed with Cutaneous Squamous Cell Cancer (CSCC)?YesNo
Are you able to understand and complete study-related questionnaires?YesNo
Submit
Cancel
Investigator
Richard Carvajal, MD
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Research Nurse Navigator
Email: cancerclinicaltrials@cumc.columbia.edu
Phone: 212-342-5162